This minireview is an update of a 1997 review on erythropoletin (EPO) in this journal (1). EPO is a 30,400-dalton glycoprotein that regulates red cell production. In the human, EPO is produced by peritubular cells in the kidneys of the adult and in hepatocytes in the fetus. Small amounts of extra-renal EPO are produced by the liver in adult human subjects. EPO binds to an erythroid progenitor cell surface receptor that includes a p66 chain, and, when activated, the p66 protein becomes dimerized. EPO receptor activation induces a JAK2 tyrosine kinase, which leads to tyrosine phosphorylation of the EPO receptor and several proteins. EPO receptor binding leads to intracellular activation of the Ras/mitogen-activated kinase pathway, which is involved with cell proliferation, phosphatidylinositol 3-kinase, and STATS 1, 3, 5A, and 5B transcriptional factors. EPO acts primarily to rescue erythroid cells from apoptosis (programmed cell death) to increase their survival. EPO acts synergistically with several growth factors (SCF, GM-CSF, 1L-3, and IGF-1) to cause maturation and proliferation of erythroid progenitor cells (primarily colony-forming unit-E). Oxygen-dependent regulation of EPO gene expression is postulated to be controlled by a hypoxia-inducible transcription factor (HIF-1α). Hypoxia-inducible EPO production is controlled by a 50-bp hypoxia-inducible enhancer that is approximately 120 bp 3' to the polyadenylation site. Hypoxia signal transduction pathways involve kinases A and C, phospholipase A2, and transcription factors ATF-1 and CREB-1. A model has been proposed for adenosine activation of EPO production that involves protein kinases A and C and the phospholipase A2 pathway. Other effects of EPO include a hematocrit-independent, vasoconstriction-dependent hypertension, increased endothelin production, upregulation of tissue renin, change in vascular tissue prostaglandins production, stimulation of angiogenesis, and stimulation of endothelial and vascular smooth muscle cell proliferation. Recombinant human EPO (rHuEPO) is currently being used to treat patients with anemias associated with chronic renal failure, AIDS patients with anemia due to treatment with zidovudine, nonmyeloid malignancies in patients treated with chemotherapeutic agents, perioperative surgical patients, and autologous blood donation. A novel erythropolesis-stimulating factor (NESP, darbepoetin) has been synthesized and when compared with rHuEPO, NESP has a higher carbohydrate content (52% vs 40%), a longer plasma half-life, the amino acid sequence differs from that of native human EPO at five positions, and has been reported to maintain hemoglobin levels just as effectively in patients with chronic renal failure as rHuEPO at less frequent dosing. The use of rHuEPO and darbepoetin to enhance athletic performance is officially banned by most sports-governing bodies because the excessive erythrocytosis can lead to increased thrombogenicity and can cause deep vein, coronary, and cerebral thromboses.
CarnotP, DeFlandreC. Sur l'activite hemopoietique de serum au cours de la regeneration du sang. C R Acad Sci (Paris)143: 384386, 1906.
3.
GibelliC. Uber den wert des serums anamisch gemachten tiere bei der regeneration des blutes. Arch Exp Pathol Pharmacol65: 284302, 1911.
4.
SandorG. Uber die blutbidende wirkung des serums von tieren, die in verdunnter luft gehalten wuren. Z Gesante Exp Med82: 633646, 1932.
5.
HjortE. Reticulocyte increase after injection of anemic serum. Mag F Laegividensk97: 270277, 1936.
6.
KrumdieckN. Erythropoietic substance in the serum of anemic animals. Proc Soc Exp Biol Med54: 1417, 1943.
7.
ErslevAJ. Humoral regulation of red cell production. Blood8: 349357, 1953.
8.
ReissmannKR. Studies on the mechanism of erythropoietin stimulation in parabiotic rats during hypoxia. Blood5: 347380, 1950.
9.
JacobsonLO, GoldwasserE, FriedW, PlzakL. Role of the kidney in erythropoiesis. Nature179: 633, 1957.
10.
FisherJW, BirdwellBJ. Erythropoietin production by the in situ perfused kidney. Acta Haematol26: 224232, 1961.
11.
KuratowskaZ, LewartowskiB, MichalskiE. Studies on the production of erythropoietin by isolated perfused organs. Blood18: 527534, 1961.
12.
ErslevAJ. In vitro production of erythropoietin by kidneys perfused with a serum free solution. Blood44: 7785, 1974.
13.
KouryST, BondurantMS, KouryMJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood71: 524537, 1988.
14.
FisherJW, KouryS, DuceyT, MendelS. Erythropoietin (Epo) production by interstitial cells of hypoxic monkey kindeys. Br J Haematol95: 2732, 1996.
15.
ZanjaniED, PosterJ, BurlingtonH, MannLI, WassermanLR. Liver as the primary site of erythropoietin production in the fetus. J Lab Clin Med89: 640644, 1977.
16.
KouryST, BondurantMC, KouryMJ, SemenzaGL. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood77: 24972503, 1991.
17.
MiyakeT, KungCKH, GoldwasserE. Purification of human erythropoietin. J Biol Chem252: 55585564, 1977.
18.
LinFK, SuggsS, LinCH, BrowneJK, SmailingR, EgricJC, ChenKK, FoxGM, MartinF, WasserZ. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A92: 78507884, 1985.
19.
JacobsK, ShoemakerC, RudersdorfR, NeillSD, KaufmanRJ, MufsonA, SeehraA, JonesSS, HewickR, FritschEF, KawakitaM, ShimizaT, MiyokeT. Isolation and characterization of genomic cDNA clones of human erythropoietin. Nature313: 806810, 1985.
20.
EgrieJC, BrowneJK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer84(Suppl 1):310, 2001.
LacombeC, DaSilvaJL, BrunevalP, FournierJG, WendlingF, CasadevallN, CamilleriJP, BarietyJ, VaretB, TambourinP. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest81: 620623, 1988.
23.
SemenzaGL, KouryST, NejfeltMK, GearhartJD, AntonarakisSE. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci U S A88: 87258729, 1991.
24.
DarbyIA, EvansBA, FuP, LimGM, MoritzKM, WintourEM. Erythropoietin gene expression in fetal and adult sheep kidney. Br J Haematol89: 266270, 1995.
25.
MaxwellAP, LappinTR, JohnstonJ, BridgesCF, McGeownMG. Erythropoietin production in kidney tubular cells. Br J Haematol74: 535539, 1990.
26.
LoyaF, YangY, LinH, GoldwasserE, AlbitarM. Transgenic mice carrying the erythropoietin gene promoter linked to lacZ express the reporter in proximal convoluted tubule cells after hypoxia. Blood84: 18311836, 1994.
27.
MujaisSK, BeryN, PullmanTN, GoldwasserE. Erythropoietin is produced by tubular cells of the rat kidney. Cell Biochem. Biophysics30: 153166, 1999.
28.
SmithDH, MaplesPB, BeruN, GoldwasserE. Identification of erythropoietin producing cells in mammalian kidneys by in situ hybridization. Blood68: 170A, 1986.
29.
RichIN, NoeGI, VogtCA, L'emkeC. Erythropoietin is produced in the tubules of the renal cortex. Blood76 (Suppl 1): 639A, 1990.
30.
Da SilvaJL, SchwartzmanML, GoodmanA, LevereRD, AbrahamNG. Localization of erythropoietin mRNA in the rat kidney by polymerase chain reaction. J Cell Biochem54: 239246, 1994.
31.
GregoryCJ, EavesAC. Human marrow cells capable of erythropoietic differentiation in vitro: definition of three erythroid colony responses. Blood49: 855864, 1974.
32.
GregoryCJ, EavesAC. Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biologic properties. Blood51: 527537, 1978.
33.
WuH, LiuX, JaenischR, LodishHF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell83: 5967, 1995.
34.
LinCS, LimSK, D'agatiV, CostantiniF. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genus Dev10: 154164, 1996.
35.
WuH, KlingmullerU, BesmerP, LodishHF. Interaction of the erythropoietin and stem-cell-factor receptors. Nature377: 242246, 1995.
36.
Jacobs-HelberSM, PentaK, SunZ, LawsonA, SawyerST. Distinct signaling from stem cell factor and erythropoietin in HCD57 cells. J Biol Chem272: 68506853, 1997.
37.
DessyprisEN, GleatonJH, ArmstrongOL. Effect of human recombinant erythropoietin on human marrow megakaryocyte colony formation in vitro. Br J Haematol65: 265269, 1987.
SawadaK, KrantzSB, DaiC-H, KouryST, HornST, GlickAD, CivinCI. Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptor. J Cell Physiol142: 219230, 1990.
40.
WickremaA, KrantzSB, WinkelmannJC, BondurantMC. Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood80: 19401949, 1992.
41.
SawyerST, KouryMJ. Erythropoietin requirement during terminal erythroid differentiation: the role of surface receptors for erythropoietin (Abs). J Cell Biol105: 1077, 1987.
42.
D'andreaAD, LodishHF, WongGG. Expression cloning of the murine erythropoietin receptor. Cell57: 277285, 1989.
43.
LivuahO, SturaEA, MiddletonSA, JohnsonDC, JokiffeCK, WilsonTA. Crystallographic evidence for performed divers of erythropoietin receptor before ligand activation. Science283: 987990, 1999.
44.
RemyI, WilsonIA, MichnickSW. Erythropoietin receptor activation by a ligand-induced conformation change. Science283: 990993, 1999.
45.
PhiloJS, AokiKH, ArkawsT, NahriLO, WenJ. Dimerization of the extracellular domain of the erythropoietin (Epo) receptor by Epo: one high-affinity and one low-affinity interaction. Biochemistry35: 16811691, 1996.
46.
KubatzkyKK, RuanW, GurezkaR, CohenJ, KettelrR, Watowich, NeumannD, LangoschD, KlingmullerU. Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor. Curr Biol11: 110115, 2001.
47.
ConstantinescuJN, KerenT, SocolovskyM, NamH, HenisYI, LodishHF. Ligand-independent oligomerizatin of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A98: 43794384, 2001.
48.
MayeuxP, LacombeC, CasadevallN, ChretienS, DusanterI, GisselbrechtS. Structure of the murine erythropoietin receptor complex. Characterization of the erythropoietin cross-linked proteins. J Biol Chem266: 2338023385, 1991.
49.
QiuH, BelangerA, YoonHW, BunnHF. Homodimerization restores biological activity to an inactive erythropoietin mutant. J Biol Chem273: 1117311176, 1998.
50.
WitthuhnB, QuelleFW, SilvennoinenO, YiT, TangB, MiuraO, IhleJN. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following Epo stimulation. Cell74: 227236, 1996.
51.
HiltonCJ, BerridgeMV. Conserved region of the cytoplasmic domain is not essential for erythropoietin-dependent growth. Growth Factors121: 263276, 1995.
52.
MiuraO, D'andreaA, KabatD, IhleJN. Induction of tyrosine phosphorylation by the erythropoietin receptor correlates with mitogenesis. Mol Cell Biol11: 48954902, 1991.
53.
YoshimuraA, LodishHF. In vitro phosphorylation of the erythropoietin receptor and an associated protein, pp130. Mol Cell Biol12: 706715, 1992.
ZangH, SatoK, NakajumaH, McKayC, NeyPA, IhleJN. The distal region and receptor tyrosines of the EPO receptor are non-essential for in vivo erythropoiesis. EMBO J20: 31563166, 2001.
56.
Von LindernM, Parren-Von AmehvortM, Von DijkT, DeinerE, Von Den AkkerE, Von Erst-de VriesS, WilliamsP, BengH, LowenbergB. Protein kinase c-α controls erythropoietin receptor signaling. J Biol Chem275: 3471934727, 2000.
57.
KouryMJ, SawyerST, BrandtSJ. New insights into erythropoiesis. Curr Opin Hematol9: 93100, 2002.
58.
CarrolMP, SpivakJL, McMahonM, WeichN, RappUR, MayWS. Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation. J Biol Chem266: 1496414969, 1991.
59.
GobertS, DuprezV, LacombeC, GisselbrechtS, MayeuxP. Erythropoietin activates three forms of MAP kinase in UT7 erythroleukemia cells. Eur J Biochem234: 7583, 1995.
60.
MiuraY, MuiraO, IhleJN, AokiN. Activation of the mitogen activated protein kinase pathway by the erythropoietin receptor. J Biol Chem269: 2996229969, 1994.
61.
DamenJE, MuiALF, PuilL, PawsonT, KrystalG. Phosphatidylinositol 3-kinase associates, via its Src homology 2 domains, with the activated erythropoietin receptor. Blood81: 32043210, 1996.
62.
DamenJ, CutlerRL, JiaoH, YiT, KrystalG. Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the p85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity. J Biol Chem270: 2340223406, 1995.
63.
VerdierF, ChrétienS, BillatC, GisselbrechtS, LaCombeC, MayeuxP. Erythropoietin induces the tyrosine phosphorylation of insulin receptor substrate-2: an alternate pathway for erythropoietin-induced phosphatidylinositol 3-kinase activation. J Biol Chem272: 2617326178, 1997.
64.
PallardC, FabriceG, MartineC, GronerB, GisselbrechtS, Dusanter-FourtI. Interleukin-3, erythropoietin, and prolactin activate a STAT5 line factor in lymphoid cells. J Biol Chem270: 1594215945, 1995.
65.
WakaoH, HaradaN, KitamuraT, MuiALF, MiyajimaA. Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways. EMBO J14: 25272535, 1995.
66.
PentaK, SawyerST. Erythropoietin induces the tyrosine phosphorylation nuclear translocation and DNA binding of STAT1 and STAT5 in erythroid cells. J Biol Chem270: 3128231287, 1995.
67.
WatowichSS, MikamiA, BuscheRA, XieX, PharrPN, HongmoreGD, ManduitP, SabbahM, DrukerB, VainchenkerW, FisherS, LacombeC, GisselbrecchtS. Erythropoietin receptors that signal through Stat5 or Stat3 support fetal liver and adult erythropoiesis: lack of specificity of STAT signals during Red Blood Cell Development. J Interferon Cytokine Res20: 10651070, 2000.
DamenJE, WakaoH, MiyajimaA, KroslJ, HumphriesRK, CutlerRL, KrystalG. Tyrosine 343 in the erythropoietin-receptor positively regulates erythropoietin-induced cell proliferation and STAT5 activation. EMBO J14: 55575568, 1995.
70.
ChrétienS, VarletP, VerdierF, GobertS, CartronJP, GisseelbrechtS, MayeuxP, LaCombeC. Erythropoietin-induced differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation. EMBO J15: 41744181, 1996.
71.
KlingmullerU, BergelsonS, HsiaoJG, LodishHC. Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5. Proc Natl Acad Sci U S A93: 83248328, 1996.
72.
QuelleFW, WangD, NosakaT, ThierfelderWE, StravopidisD, WeinsteinY, IhleJN. Erythropoietin induces the activation of STAT5 through association with specific tyrosines on the receptor that are not required for a mitogenic response. Mol Cell Biol16: 16221631, 1996.
73.
TauchiT, DamenJE, ToyamaK, FengGS, BroxmeyerHE, KrystalG. Tyrosine 426 within the activated erythropoietin receptor binds Syp reduces the erythropoietin required for Syp tyrosine phosphorylation and promotes mitogenesis. Blood87: 44954501, 1996.
74.
KlingmullerU, LorenzU, CantleyLC, NeelBC, LodishHC. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes activation of JAK2 and termination of proliferative signals. Cell80: 729738, 1995.
75.
ShanR, PriceJO, GuardeWA, MoniaBP, KrantzSB, ZhaoZJ. Distinct roles of JNKs/p38 MAP kinase and ERKs in apoptosis and survival of HCP-57 cells induced by withdrawal or addition of erythropoietin. Blood94: 40674076, 1999.
76.
Jacobs-HelberSM, RyanSM, SawyerJJ. JNK p38 are activated by erythropoietin in (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD 57 cells. Blood96: 933940, 2000.
77.
KrantzSB, ZhaoZJ. Retraction. Blood97: 843, 2001.
78.
SemenzaGL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Biol15: 551578, 1999.
79.
ZhuH, BunnHF. How do cells sense oxygen?Science292: 449451, 2001.
80.
IvanM, KondoK, YangH, KimW, ValiandoJ, OhhM, SalicA, AsaraJM, LaneWS, KaclinWGJr.. HIF α targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science292: 464468, 2001.
81.
JiangBH, RueE, WangGL, RoeR, SemenzaGL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. Am Soc Biochem Mol Biol271: 1777117778, 1996.
82.
WangGL, SemenzaGL. General involvement of hypoxia-inducible factor 1 in transcriptional responses to hypoxia. Proc Natl Acad Sci U S A90: 43044308, 1993.
83.
SemenzaGL, NejfeltMkl, ChiSM, AntonarakisSE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci U S A88: 56805684, 1991.
84.
BeckI, RamirezS, WeinmannR, CaroJ. Enhancer element at the 3'-flanking region controls transcriptional response to hypoxia in the human erythropoietin gene. J Biol Chem266: 1556315566, 1991.
85.
SemenzaGL, WangGl. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required or transcriptional activation. Mol Cell Biol12: 54475454, 1992.
86.
BeckI, WeinmannR, CaroJ. Characterization of hypoxia-responsive enhancer in the human erythropoietin gene shows presence of hypoxia-inducible 120-Kd nuclear DNA-binding protein in erythropoietin-producing and nonproducing cells. Blood82: 704711, 1993.
87.
WangGL, SemenzaGL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem268: 2151321518, 1993.
88.
WangGL, SemenzaGL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem270: 12301237, 1995.
89.
HoffmanEC, ReyesH, ChuFF, SanderF, ConleyLH, BrooksBA, HankisnonO. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science252: 954958, 1991.
90.
GoldbergMA, DunningSP, BunnHF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science242: 14121415, 1988.
91.
WangGL, SemenzaGL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA binding activity: implications for models of hypoxia signal transduction. Blood82: 36103615, 1993.
92.
JiangB-H, ZhengJZ, LeungSW, RoeR, SemenzaGL. Transactivation and inhibitory domains of hypoxia-inducible factor 1 α: modulation of transcriptional activity by oxygen tension. J Biol Chem272: 1925319260, 1997.
93.
ChandelNS, MaltepeE, GoldwasserE, MàthieuCE, SimonMC, SchumackerPT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A95: 1171511720, 1998.
94.
FandreyJ, FredeS, EhlebenW, PorwolT, AckerH, JelkmannW. Cobalt chloride and desferrioxamine antagonize the inhibition of erythropoietin production by reactive oxygen species. Kidney Int51: 492496, 1997.
95.
MaxwellPH, WiesenerMS, ChangG-W, CliffordSC, VauxEC, CockmanME, WykoffCC, PughCW, MaherEA, RatcliffePJ. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature399: 271275, 1999.
96.
LiuY, ChristouH, MoritaT, LaughnerE, SemenzaGL, KourembanasS. Carbon monoxide and nitric oxide suppresses the hypoxic induction of vascular endothelial growth factor gene via the 5' enhances. J Biol Chem273: 1525715262, 1998.
97.
SogawaK, Numayama-TsurutaK, EmaM, AbeM, AbeH, Fujii-KuriyamaY. Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia. Proc Natl Acad Sci U S A95: 73687373, 1998.
98.
GleadleJM, EbertBL, RatcliffePJ. Diphenylene iodonium inhibits the induction of erythropoietin and other mammalian genes by hypoxia: implication for the mechanism of oxygen sensing. Eur J Biochem234: 9299, 1995.
99.
WangGL, JiangB-H, SemenzaGL. Effect of altered redox states on expression and DNA-binding activity of hypoxia-inducible factor 1. Biochem Biophys Res Commun212: 550556, 1995.
100.
JaakolaP, MoleDR, Ya-MinTian, WilsonMI, GlelburtJ, GaskettJJ, Von KriegshelmA, HebestreitHF, MukerjiM, SchofieldD, MaxwellPH, PreghCW, RatcliffePJ. Targeting of HIF-α to the von hippellindau ubiquitylation complex by O2-regulated prolyl hydroxylationScience292: 468472, 2001.
101.
KivirikkoKI, PihlajaniemiI. Collagen hydroxylases and the protein disulfide isomerase subunit of polyl 4-hydroxylases. Adv Enzymol Relat Areas Mol Biol72: 325398, 1998
102.
SemenzaGL. HIF-1 O2 and 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell107: 13, 2001.
103.
OhhM, ParkCW, IvanM, HoffmanMA, KimT-Y, HuangLE, PavletichN, ChouV, KaelinWG. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von hipple-lindau protein. Nat Cell Biol2: 423427, 2000.
104.
MassonN, WilliamC, MaxwellPH, PughCW, RatcliffePJ. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J20: 51975206, 2001.
105.
EpsteinCRA, GleadleJM, McNeillLA, HeurtsonKS, O'rourkeJ, MoleDR, MukherjiM, MetzernE, WilsonMI, DhondaA, TianY-M, MassonN, HamiltonDL, JaakkoalP, BarsteadR, HodgkinJ, MaxwellPH, PughCW, SchofieldCJ, RatcliffePJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell107: 4354, 2001.
106.
BruickRK, McKnightSL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science294: 13371340, 2001.
107.
KallioPJ, OkamotoK, ObrienS, CarreroP, MakinoY, TanakaH, PoellingerL. Signal transduction in hypoxic cells: inducible translocation and recruitment of the CBP/P300 coactivator by the hypoxia-inducible factor-1α. EMBO J17: 65736586, 1998.
108.
WangGL, JiangB-H, SemenzaGL. Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Biochem Biophys Res Commun216: 669675, 1995.
109.
KvietikovaI, WengerRH, MartiHH, GassmanM. The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site. Nucleic Acids Res23: 45424550, 1995.
110.
UenoM, BrookinsJ, BeckmanB, FisherJW. A1 and A2 Adenosine receptor regulation of erythropoietin production. Life Sci43: 229237, 1988.
111.
MentzerRMJr., RubioR, BerneRM. Release of adenosine by hypoxic canine lung tissue and its possible role in pulmonary circulation. Am J Physiol229: 16251631, 1975.
112.
MinaminoT, KitakazoM, KomamuraK, NodeH, TakedaH, InouseM, HoriM, KamadaT. Activation of protein kinase C increases adenosine production in the hypoxic canine coronary artery through the extracellular pathway. Arterioscler Thromb Vasc Biol15: 22982304, 1995.
113.
KobayashiS, MillhornDE. Stimulation of expression for the adenosine A2A receptor gene by hypoxia in PC12 cells. A potential role in cell protection. J Biol Chem274: 2035820365, 1999.
114.
BakrisGR, SauterER, HusseyJL, FisherJW, GaberAO, WinsettR. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med323: 8690, 1990.
115.
FisherJW, BrookinsJ. Adenosine A2A and A2B receptor activation of erythropoietin production. Am J Physiol281: F826F832, 2001.
116.
NakashimaJ, OhigashiT, BrookinsJW, BeckmanBS, AgrawalKC, FisherJW. Effects of 5-N-ethylcarboxamideadenosine on erythropoietin production. Kidney Int44: 734740, 1993.
117.
OhigashiT, NakashimaJ, AggarwalS, BrookinsJ, AgrawalK, FisherJW. Enhancement of erythropoietin production by selective adenosine A2 recepton agonists in response to hypoxia. J Lab Clin Med126: 299306, 1995.
YoshiokaK, ClejanS, BrookinsJ, FisherJW. Activation of protein kinase C in human hepatocellular carcinoma (HEP3B) cells increases erythropoietin production. Life Sci63: 523535, 1998.
120.
McGaryEC, RondonIJ, BeckmanBS. Post-transcriptional regulation of erythropoietin mRNA stability by eyrthropoietin mRNA-binding protein. Proc Natl Acad Sci U S A88: 51495153, 1997.
121.
BouritiusH, BojvothRB, GrootJA. Microelectrode measurements of the effects of basolateral adenosine in polarized human intestinal epithelial cells in culture. Pflugers Arch Eur J Physiol437: 589595, 1999.
122.
MichoudMC, TaoFC, PradhamAA, MartinJG. Mechanisms of the potentiation by adenosine of adenosine triphosphate-induced calcium release in tracheal smooth muscle cells. Am J Resp Cell Mol Biol21: 3036, 1999.
123.
EschbachJW, EgrieJC, DowningMR, BrowneJK, AdamsonJW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med316: 7378, 1987.
124.
EschbachJ, DeOreoP, AdamsonJrHuEPO clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis30(Suppl 3): S192S240, 1997.
125.
EschbachJW. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI. Semin Nephrol20: 320329, 2000.
126.
KaufmanJS, RedaDJ, FyeCL, GoldfarbD, HendersonWG, KleinmanJG, VaamondeCA. Subcutaneous versus intravenous administration of erythropoietin in hemodialysis patients. N Engl J Med339: 578583, 1998.
127.
EgrieJC, EschbachJW, McGuireT, AdamsonJW. Pharmacokinetics of recombinant human erythropoietin administered to hemodialysis (HD) patients. Kidney Int33: 262, 1988.
128.
EschbachJW, HaleyNR, AdamsonJW. The use of recombinant erythropoietin in the treatment of the anemia of chronic renal failureAnn NY Acad Sci554: 225230, 1989.
129.
JacobsC, HorlWH, MacdougalTC, ValderrabanoF, ParrondoI, SegnerA, AbrahamTL. European best practice guidelines 5 target haemoglobin. Nephrol Dial Transplant15(Suppl 4):1519, 2000.
130.
FisherJW, BommerJ, EschbachJ, FriedW, LangeRD, MassryS, NathanD, NolphKD, TeehanBP. Statement on the clinical use of recombinant erythropoietin in anemia of end stage renal disease. Am J Kidney Dis14: 163169, 1989.
131.
MurphyST, ParfreyPS. Erythropoietin therapy in chronic anemia: the impact of normalization of hematocrit. Curr Opin Nephrol Hypertens8: 573578, 1999.
132.
KesslerM. Value of early management of patients with chronic renal failure. Presse Medicale26: 13401342, 1997.
133.
RitzE, EisenhartA. Early epoetin treatment in patients with renal insufficiency. Nephrol Dialysis Transplant15(Suppl 3):4044, 2000.
134.
GarciaMM, BeckmanBS, BrookinsJW, PowellJS, LanhamW, BlaisdellS, KeayL, LiSC, FisherJW. Development of a new radioimmunoassay for EPO using recombinant erythropoietin. Kidney Int38: 969975, 1990.
135.
McGonigleRJS, BoineauFG, Ohene-FrempongK, LewyJE, ShadduckRK, FisherJW. Erythropoietin and inhibitors of in vitro erythropoiesis in the development of anemia in children with renal disease. J Lab Clin Med105: 449481, 1985.
136.
RadtkeHW, RegeAB, LamarcheMB, BartosD, CampbellRA, FisherJW. Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest67: 16231629, 1980.
137.
MacdougallIC. Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int59(Suppl 78):567572, 2001.
138.
KushnerDS, BeckmanBS, NguyenL, ChenS, Della SantinaC, HusserlF, RiceJ, FisherJW. Poyamines in the anemia of end stage renal disease (ESRD). Kidney Int39: 725732, 1991.
139.
AllenDA, BreenC, YagoogMM, MacDougallIC. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-α and TNF-α. J Invest Med47: 204211, 1999.
140.
ErslevAJ, BesarebA. The rate and control of baseline red cell production in hematologically stable patients with uremia. J Lab Clin Med126: 283286, 1995.
141.
SteinerRW. Characteristics of the hematocrit response to continuous ambulatory dialysis. Arch Intern Med144: 728732, 1984.
142.
McGonigleRJS, HusserlF, WallinJD, FisherJW. Hemodialysis and continuous ambulatory peritoneal dialysis effect on erythropoiesis in renal failure. Kidney Int25: 430436, 1984.
143.
VaziriNA. Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens10: 633637, 2001.
144.
VaziriND, ZhouXJ, NaquiF, SmithJ, OveisiF, WangZQ. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol271: E113E122, 1996.
145.
KoupkeCJ, KimS, VaziriND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol4: 18741878, 1994.
146.
VaziriND, ZhouM, SmithJ, OveisiF, BaldwinK, PurdyRD. In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol269: F838F845, 1995.
147.
Bode-BogerSM, BogerRH, KahnM, RodermacherJ, FrohlichJC. Recombinant erythropoietin enhances vasoconstriction tone via endothelin-1 and constrictor prostanoids. Kidney Int50: 12551261, 1996.
148.
BrochuE, LacassesS, LariviereR, KingmaI, GroseJH, LebelM. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol10: 14401446, 1999.
149.
EggenaP, WillseyP, JarngotchianN, TruckenbrodL, BarrettJD, EggenaMP, CleggK, NakhoulF, LeeDBN. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol261: E642E646, 1991.
150.
Bode-BogerSM, BogerRH, KuhnM. Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J Cardiovasc Pharmacol20(Suppl 12):525528, 1992.
151.
PelletierL, RegnardJ, FellmanD, ChrarbordP. An in vitro model for the study of human marrow angiogenesis: role of hematopoietic cytokines. Lab Investig80: 501511, 2000.
152.
RibattiD, PrestaM, VascaA, GiulianiRR, Dell'EraP, RoncaliNB, DammacoF. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood93: 26272636, 1999.
153.
CarliniRG, ReyesAA, RothsteinM. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int47: 740745, 1995.
Jereen-SturgicB, RaceV, JerenT, Horavatin-GolderS. Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin. Angiology51: 131139, 2000.
156.
WagnerKF, KatschinskiDM, HasegawaJ, SchumacherD, MellerB, GembruckV, SchrammV, JelkmannW, GassmannM, FandreyJ. Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood97: 536542, 2001.
157.
CasadevallN, NatafJ, VironB, KoltaA, KiladjianJ-J, DupontPM, MichaudP, PapoT, UgoV, TeyssanderI, VaretB, MayeuxP. Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med346: 469475, 2002.
158.
GogueSR, BeckmanBS, WilsonRB, AgrawalKS. Inhibitory effects of zidovudine in erythroid progenitor cells. Reversal with a combination of erythropoietin and interleukin-3. Biochem Pharmacol50: 413419, 1995.
159.
HenryDH, BealGN, BensonCA, CaryJ, ConeLA. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Ann Int Med117: 730748, 1992.
160.
FischlM, GalpinJE, LevineJL, GroopmanJE, HenryDH, KennedyP, MilesS, RobbinsW, StarrettB, ZaluskyR, AbelsRI, TsaiHC, RudnickSA. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med. 322: 14881493, 1990.
161.
SmithDH, GuaneriCM, WhalingSM, VokesEE. Erythropoietin response in cancer patients receiving cisplatin. Proc Am Assoc Cancer Res29: 52, 1988.
162.
GabriloveJL, CleelandCS, LivingstonRB, SarakhamB, WinerE, EinhornLH. Clinical evaluation of once-weekly dosing of epoetin-α in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three times weekly dosing. J Clin Oncol19: 28752882, 2001.
163.
VercameenE, RappaportB. Effects of epoetin-α on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol19: 28652874, 2001.
164.
De AndradeJR, JoveM. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin-α in patients undergoing major orthopedic surgery. Am J Orthoped25: 533546, 1996.
165.
GoldbergMA, McCutchenJW. A safety and efficacy comparison study of two dosing regimens of epoetin-α in patients undergoing major orthopedic surgery. Am J Orthoped25: 544552, 1996.
166.
Di RaimondoF, LongoG, CacciolaEJR, MiloneG, PalumboGA, CacciolaRR, AlessiM, GiustolisiR. A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. Eur J Haematol56: 711, 1996.
PriceTR, GoodnoughLT, VoglerWR, SacherRA, HellmanRM, JohnstonMFM, BolgianoDC, AbelsRI. The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial. Transfusion36: 2931, 1996.
169.
HarrisSA, PayneGJr., PutmanJM. Erythropoietin treatment of erythropoietin-deficient anemia without renal disease during pregnancy. Obstet Gynecol87: 812814, 1996.
170.
PincusT, OlsenNJ, RusselIJ, EolfeF, HarmsRE. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med89: 161168, 1990.
171.
MesserJ, HaddadJ, DonatoL, AstrucD, MatisJ. Early treatment of premature infants with recombinant human erythropoietin. Pediatrics92: 519523, 1993.
172.
BaderB, BlondheinO, JonaR, AdmoniO, Abend-WingerM, ReichD, LanisA, TamierA, EldarT, AttiasD. Decreased ferritin levels despite iron supplementation, and during therapy in the anemia of prematurity. Acta Paediatr85: 496501, 1996.
173.
SteegmanJL, LopezJ, OteroMJ, LamanaML, de la CámaraR, BarberanaM, DiazA, Ferńandeź-RanadaJM. Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial. Bone Marrow Transplant10: 541546, 1992.
174.
PierelliL, ScambiaG, MenichellaG, D'onofrioG, SlernoG, PaniciPB, FoddaiML, VittoriM, LaiM, CiarliM, PugliaG, MancusoS, BizziB. The combination of erythropoietin and granulocyte colony-stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation. Br J Haematol92: 287294, 1996.
175.
GoodnoughLT, AndersonKC, KurtzS, LaneTA, PisciottoPT, SilversteinLE. Indications and guidelines for the use of hematopoietic growth factors. Committee Rep Transfus33: 944955, 1993.
176.
EschbachJW, AbdulhadiMH, BrowneJK, DelanoBG. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Int Med111: 9921000, 1989.
177.
EgrieJC, GrantJR, GilliesDK. The role of the carbohydrate on the biological activity of erythopoietin. Glycoconjugate J10: 263, 1993.
178.
MacdougallIC, GraySJ, ElstonO, BreenC, JenkinsB, BrowneJ, EgrieJ. Pharmacokinetics of novel erythropoieis protein compared with epoetin-α in dialysis patients. J Am Soc Nephrol10: 23922395, 1999.
179.
MacdougallIC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dialysis Transplant16(Suppl 3):1421, 2001.
180.
LocatelliF, OlivaresJ, WalkerR, WilkieM, JenkinsB, DeweyC, GraySJ. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int60: 741747, 2001.
181.
MacdougallIC, RobertsDE, ColesGA, WilliamsJD. Clinical pharmacokinetics of epoetin (recombinant human erthropoietin). Clin Pharmacokinetics20: 99113, 1991.
182.
MacdougallIC, GarySJ, ElstonO, BreenC, JenkinsB, BrowneJ, EgrieJ. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin-α in dialysis patients. J Am Soc Nephrol10: 23922395, 1999.
183.
Macdougall IC, on behalf of the UK NESP Study Guide.Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anemia. J Am Soc Nephrol9: 258A259A, 1998.
184.
KorbertSM. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis. Kidney Int43: S111S119, 1993.
185.
VanrenterghemY, BaranyP, MannJ. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin in ESRD patients when administered once-weekly or once every other week. J Am Soc Nephrol10: 270A, 1999.
186.
The Medical Letter on Drugs, and Therapeutics. Darbepoetin (ARANESP) = a long-acting erythropoietin. Rochelle, NY: The Medical Letter, Inc. Vol. 43(1120) pp 109110, 2001.
187.
PaceN. The increase in hypoxia tolerance of normal men accompanying the polycythemia induced by transfusion of erythocytesAm J Physiol148: 152163, 1947.
188.
EkblomB, GoldbardAN, GullbringB. Response to exercise after blood loss and reinfusion. J Appl Physiol33: 175180, 1972.
189.
EkblomB, BerglundB. Effect of erythropoietin administration on maximal aerobic power. Scand J Med Sci Sports1: 8893, 1991.
190.
JelkmannW. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharmaceut Biotechnol1: 1131, 2000.
191.
JelkmannW. Beneficial and adverse effects of erythropoietin therapy. In: PetersC, SchulzT, MichnamH, Druck, Eds. Biomedical Side Effects of DopingGermany: Hansen, Bergisch Gladbach, pp 5973, 2001.
BreymannC. Erythropoietin test methods. Best Practice Res Clin Endocrinol Metab14: 135145, 2000.
194.
SieffCA, NathanDG. Haemopoietic stem cells. In: WeatherallDJ, LedinghamJGG, WarrenDA, Eds. Oxford Textbook of Medicine (3rd ed). Oxford, UK: Oxford University Press, pp 33813390, 1996.
195.
MartiHH, BernaudinM. Function of erythropoietin in the brain. In: WolfgangJ, Ed. Erythropoietin: Molecular Biology and Clinical Use. Johnson City, Tennessee: F. P. Graham Publishing Co., pp 195215, 2002.
196.
JuulS. Erythropoietin in the central nervous system and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr438(Suppl):3642, 2002.
